ZA200508831B - Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders - Google Patents
Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders Download PDFInfo
- Publication number
- ZA200508831B ZA200508831B ZA200508831A ZA200508831A ZA200508831B ZA 200508831 B ZA200508831 B ZA 200508831B ZA 200508831 A ZA200508831 A ZA 200508831A ZA 200508831 A ZA200508831 A ZA 200508831A ZA 200508831 B ZA200508831 B ZA 200508831B
- Authority
- ZA
- South Africa
- Prior art keywords
- carboxamide
- azetidine
- trifluoromethyl
- butyl
- dichlorobenzhydryloxy
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 230000001404 mediated effect Effects 0.000 title claims abstract description 8
- PVXOUGHWLCBJOW-UHFFFAOYSA-N azetidine-1-carboxamide Chemical class NC(=O)N1CCC1 PVXOUGHWLCBJOW-UHFFFAOYSA-N 0.000 title claims description 61
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 title abstract 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 59
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 125000003118 aryl group Chemical group 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 208000008589 Obesity Diseases 0.000 claims abstract description 14
- 235000020824 obesity Nutrition 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- 239000000651 prodrug Substances 0.000 claims abstract description 4
- 229940002612 prodrug Drugs 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- -1 3-(2,4'-dichlorobenzhydryloxy)-N-(3-ethoxypropyl)azetidine-1-carboxamide 3-(2,4'-dichlorobenzhydryloxy)-N-(2-tetrahydrofuranylmethyl)azetidine-1-carboxamide Chemical compound 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000004001 thioalkyl group Chemical group 0.000 claims description 7
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 235000012631 food intake Nutrition 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000005593 norbornanyl group Chemical group 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 12
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 230000005586 smoking cessation Effects 0.000 claims 3
- 201000009032 substance abuse Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- NMQMVJQRTFTBRP-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(1-phenylpropyl)azetidine-1-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)N(C1)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 NMQMVJQRTFTBRP-UHFFFAOYSA-N 0.000 claims 1
- WWSIDXRHPVNWKU-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-[(2-methoxyphenyl)methyl]azetidine-1-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)N1CC(OC(C=2C=CC(Cl)=CC=2)C=2C(=CC=CC=2)Cl)C1 WWSIDXRHPVNWKU-UHFFFAOYSA-N 0.000 claims 1
- UOUVSTIOFTVFBW-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-(2,4,4-trimethylpentan-2-yl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)CC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 UOUVSTIOFTVFBW-UHFFFAOYSA-N 0.000 claims 1
- SXKYOXHYTLPEKN-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-cyclohexylazetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC2CCCCC2)C1 SXKYOXHYTLPEKN-UHFFFAOYSA-N 0.000 claims 1
- HWLAWTMTIUBMRV-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-prop-2-enylazetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NCC=C)C1 HWLAWTMTIUBMRV-UHFFFAOYSA-N 0.000 claims 1
- LSJZXKGOYIYDQD-UHFFFAOYSA-N 3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]-n-prop-2-enylazetidine-1-carboxamide Chemical compound C1=CC(OC(F)F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NCC=C)C1 LSJZXKGOYIYDQD-UHFFFAOYSA-N 0.000 claims 1
- WMDFBQORZPFSTC-UHFFFAOYSA-N 3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]-n-propan-2-ylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)F)C=C1 WMDFBQORZPFSTC-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- ZDEVQOADMXOMDO-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 ZDEVQOADMXOMDO-UHFFFAOYSA-N 0.000 claims 1
- JWESBCIKCOHJSY-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 JWESBCIKCOHJSY-UHFFFAOYSA-N 0.000 claims 1
- WJBNQPICTCHOQS-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-methylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 WJBNQPICTCHOQS-UHFFFAOYSA-N 0.000 claims 1
- CENFVFWZOPWHSC-UHFFFAOYSA-N n-(1-adamantyl)-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 CENFVFWZOPWHSC-UHFFFAOYSA-N 0.000 claims 1
- KJRUZQCAADTPFK-UHFFFAOYSA-N n-[(2-bromothiophen-3-yl)methyl]-3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NCC2=C(SC=C2)Br)C1 KJRUZQCAADTPFK-UHFFFAOYSA-N 0.000 claims 1
- BOEIGWVMFZGJKU-UHFFFAOYSA-N n-benzyl-3-[(4-chlorophenyl)-[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC=C1C(C=1C=CC(Cl)=CC=1)OC1CN(C(=O)NCC=2C=CC=CC=2)C1 BOEIGWVMFZGJKU-UHFFFAOYSA-N 0.000 claims 1
- AALJQBMGLBJRRK-UHFFFAOYSA-N n-benzyl-3-[[4-(trifluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NCC=2C=CC=CC=2)C1 AALJQBMGLBJRRK-UHFFFAOYSA-N 0.000 claims 1
- OGDZECLEZAVEGM-UHFFFAOYSA-N n-butan-2-yl-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(F)C=C1 OGDZECLEZAVEGM-UHFFFAOYSA-N 0.000 claims 1
- SZTJHJQPGRWWOH-UHFFFAOYSA-N n-butan-2-yl-3-[[4-(trifluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)(F)F)C=C1 SZTJHJQPGRWWOH-UHFFFAOYSA-N 0.000 claims 1
- BHSWRGGHCFTVNO-UHFFFAOYSA-N n-butan-2-yl-3-[phenyl-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=CC=C1 BHSWRGGHCFTVNO-UHFFFAOYSA-N 0.000 claims 1
- MPZMPPJJGNTVHR-UHFFFAOYSA-N n-cyclohexyl-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC2CCCCC2)C1 MPZMPPJJGNTVHR-UHFFFAOYSA-N 0.000 claims 1
- ORJHHJOWGFPRHF-UHFFFAOYSA-N n-cyclohexyl-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC2CCCCC2)C1 ORJHHJOWGFPRHF-UHFFFAOYSA-N 0.000 claims 1
- DRNWAWJUXFFRSU-UHFFFAOYSA-N n-cyclohexyl-3-[[4-(difluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(OC(F)F)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC2CCCCC2)C1 DRNWAWJUXFFRSU-UHFFFAOYSA-N 0.000 claims 1
- BNLYOVHLLDBOFZ-UHFFFAOYSA-N n-tert-butyl-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 BNLYOVHLLDBOFZ-UHFFFAOYSA-N 0.000 claims 1
- QLFCAMOXLZVIQX-UHFFFAOYSA-N n-tert-butyl-3-[(4-chlorophenyl)-[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC(F)=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 QLFCAMOXLZVIQX-UHFFFAOYSA-N 0.000 claims 1
- MBCVORKWWTUQEI-UHFFFAOYSA-N n-tert-butyl-3-[(4-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(F)C=C1 MBCVORKWWTUQEI-UHFFFAOYSA-N 0.000 claims 1
- IKANRRQTBDVMDU-UHFFFAOYSA-N n-tert-butyl-3-[(4-methoxyphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC(C)(C)C)C1 IKANRRQTBDVMDU-UHFFFAOYSA-N 0.000 claims 1
- NCZIGNURHCMRNY-UHFFFAOYSA-N n-tert-butyl-3-[(4-methylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(C)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC(C)(C)C)C1 NCZIGNURHCMRNY-UHFFFAOYSA-N 0.000 claims 1
- DCBWYROPEMAPBJ-UHFFFAOYSA-N n-tert-butyl-3-[[4-(trifluoromethoxy)phenyl]-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(OC(F)(F)F)C=C1 DCBWYROPEMAPBJ-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 description 29
- 239000003557 cannabinoid Substances 0.000 description 29
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 125000002015 acyclic group Chemical group 0.000 description 7
- 229960004242 dronabinol Drugs 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- 125000006165 cyclic alkyl group Chemical group 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002621 endocannabinoid Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 3
- 108050007331 Cannabinoid receptor Proteins 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 229940125710 antiobesity agent Drugs 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 239000002469 receptor inverse agonist Substances 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 150000001539 azetidines Chemical class 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229940121376 cannabinoid receptor agonist Drugs 0.000 description 2
- 239000003537 cannabinoid receptor agonist Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- CUJUUWXZAQHCNC-DOFZRALJSA-N 2-arachidonyl glyceryl ether Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CO)CO CUJUUWXZAQHCNC-DOFZRALJSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LAXPNMTYJFUPLS-UHFFFAOYSA-N 3-[(2-chlorophenyl)-(4-chlorophenyl)methoxy]-n-(2-methylbutan-2-yl)azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)CC)CC1OC(C=1C(=CC=CC=1)Cl)C1=CC=C(Cl)C=C1 LAXPNMTYJFUPLS-UHFFFAOYSA-N 0.000 description 1
- PTVKXSFBTUPKHX-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-tert-butylazetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Br)C=C1F PTVKXSFBTUPKHX-UHFFFAOYSA-N 0.000 description 1
- MUZSHPIDCIYXKA-UHFFFAOYSA-N 3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-n-propylazetidine-1-carboxamide Chemical compound C1N(C(=O)NCCC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 MUZSHPIDCIYXKA-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000003382 ingestive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- XHSUIMMWJMJPLV-UHFFFAOYSA-N n-(1-adamantyl)-3-[bis(2-chlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound ClC1=CC=CC=C1C(C=1C(=CC=CC=1)Cl)OC1CN(C(=O)NC23CC4CC(CC(C4)C2)C3)C1 XHSUIMMWJMJPLV-UHFFFAOYSA-N 0.000 description 1
- PQQGOZKVEOKNQU-UHFFFAOYSA-N n-butan-2-yl-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)CC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(SC)C=C1 PQQGOZKVEOKNQU-UHFFFAOYSA-N 0.000 description 1
- AMPJXPAFTWUKMF-UHFFFAOYSA-N n-butyl-3-[(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NCCCC)CC1OC(C=1C(=CC=CC=1)C(F)(F)F)C1=CC=C(Cl)C=C1 AMPJXPAFTWUKMF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NAQXOHUKTAFNDO-UHFFFAOYSA-N n-tert-butyl-3-[(4-chlorophenyl)-(2,4-dichlorophenyl)methoxy]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC(C)(C)C)CC1OC(C=1C(=CC(Cl)=CC=1)Cl)C1=CC=C(Cl)C=C1 NAQXOHUKTAFNDO-UHFFFAOYSA-N 0.000 description 1
- XMOQEKAEOOOHFV-UHFFFAOYSA-N n-tert-butyl-3-[(4-methylsulfanylphenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=1C(=CC=CC=1)C(F)(F)F)OC1CN(C(=O)NC(C)(C)C)C1 XMOQEKAEOOOHFV-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0310056 | 2003-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200508831B true ZA200508831B (en) | 2007-03-28 |
Family
ID=33397041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200508831A ZA200508831B (en) | 2003-05-01 | 2005-10-31 | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7504522B2 (sl) |
| EP (1) | EP1620395B1 (sl) |
| JP (1) | JP2006525298A (sl) |
| KR (1) | KR20060010770A (sl) |
| CN (1) | CN1802350A (sl) |
| AT (1) | ATE453620T1 (sl) |
| AU (1) | AU2004234125A1 (sl) |
| BR (1) | BRPI0409938A (sl) |
| CA (1) | CA2524251A1 (sl) |
| DE (1) | DE602004024880D1 (sl) |
| EA (1) | EA010583B1 (sl) |
| MX (1) | MXPA05011670A (sl) |
| NO (1) | NO20055654L (sl) |
| NZ (1) | NZ543016A (sl) |
| WO (1) | WO2004096763A1 (sl) |
| ZA (1) | ZA200508831B (sl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004096209A1 (en) * | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | The use of azetidinecarboxamide derivatives in therapy |
| NZ543451A (en) | 2003-06-11 | 2008-08-29 | Merck & Co Inc | Substituted 3-alkyl and 3-alkenyl azetidine derivitives |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| AU2006253842A1 (en) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| WO2007102999A2 (en) * | 2006-02-21 | 2007-09-13 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DK2234966T3 (da) * | 2007-12-18 | 2014-01-06 | Sanofi Sa | Azetidinderivater, fremstilling og terapeutisk anvendelse heraf |
| FR2925051B1 (fr) * | 2007-12-18 | 2010-05-21 | Sanofi Aventis | Derives d'azetidines,leur preparation et leur application en therapeutique |
| PT2009157006W (pt) * | 2008-06-26 | 2012-10-17 | Micro Labs Ltd | Processo de preparação de ebastina |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2014210041A1 (en) | 2013-06-25 | 2014-12-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Service | Glucan-encapsulated sirna for treating type 2 diabetes mellitus |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN105218474B (zh) * | 2015-10-22 | 2017-12-05 | 山东国邦药业股份有限公司 | (4r,5r)‑2‑二氯甲基‑4,5‑二氢‑5‑(4‑甲砜基苯基)‑4‑恶唑甲醇的合成方法 |
| CN109689045A (zh) | 2016-05-04 | 2019-04-26 | 因美制药公司 | 大麻素的局部制剂在治疗大疱性表皮松解症和相关结缔组织病症中的用途 |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
| TW201938164A (zh) | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
| EP3669876A1 (en) | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| WO2022049134A1 (en) | 2020-09-03 | 2022-03-10 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
| US11141404B1 (en) * | 2020-11-18 | 2021-10-12 | Anebulo Pharmaceuticals, Inc. | Formulations and methods for treating acute cannabinoid overdose |
| US11795146B2 (en) | 2021-10-11 | 2023-10-24 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof |
| WO2024073367A1 (en) * | 2022-09-26 | 2024-04-04 | Anebulo Pharmaceuticals, Inc. | Treatment of acute cannabinoid overdose |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
| JPH03264562A (ja) * | 1989-05-22 | 1991-11-25 | Hokuriku Seiyaku Co Ltd | ピペリジン誘導体 |
| JP3194355B2 (ja) * | 1996-10-24 | 2001-07-30 | 宇部興産株式会社 | ピペリジン化合物及びその製法 |
| EP1049672B1 (en) * | 1998-01-23 | 2003-09-17 | Vernalis Research Limited | Azetidinecarboxamide derivatives for treating cns disorders |
| GB9917386D0 (en) * | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-II |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| WO2004096209A1 (en) * | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | The use of azetidinecarboxamide derivatives in therapy |
-
2004
- 2004-04-29 AU AU2004234125A patent/AU2004234125A1/en not_active Abandoned
- 2004-04-29 CN CNA2004800115989A patent/CN1802350A/zh active Pending
- 2004-04-29 NZ NZ543016A patent/NZ543016A/en unknown
- 2004-04-29 CA CA002524251A patent/CA2524251A1/en not_active Abandoned
- 2004-04-29 US US10/552,575 patent/US7504522B2/en not_active Expired - Fee Related
- 2004-04-29 EA EA200501585A patent/EA010583B1/ru not_active IP Right Cessation
- 2004-04-29 AT AT04730296T patent/ATE453620T1/de not_active IP Right Cessation
- 2004-04-29 DE DE602004024880T patent/DE602004024880D1/de not_active Expired - Fee Related
- 2004-04-29 MX MXPA05011670A patent/MXPA05011670A/es active IP Right Grant
- 2004-04-29 EP EP04730296A patent/EP1620395B1/en not_active Expired - Lifetime
- 2004-04-29 JP JP2006506198A patent/JP2006525298A/ja active Pending
- 2004-04-29 BR BRPI0409938-9A patent/BRPI0409938A/pt not_active IP Right Cessation
- 2004-04-29 WO PCT/GB2004/001831 patent/WO2004096763A1/en active Application Filing
- 2004-04-29 KR KR1020057020649A patent/KR20060010770A/ko not_active Application Discontinuation
-
2005
- 2005-10-31 ZA ZA200508831A patent/ZA200508831B/en unknown
- 2005-11-30 NO NO20055654A patent/NO20055654L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2524251A1 (en) | 2004-11-11 |
| KR20060010770A (ko) | 2006-02-02 |
| BRPI0409938A (pt) | 2006-04-25 |
| CN1802350A (zh) | 2006-07-12 |
| DE602004024880D1 (de) | 2010-02-11 |
| EP1620395B1 (en) | 2009-12-30 |
| EA200501585A1 (ru) | 2006-06-30 |
| NO20055654D0 (no) | 2005-11-30 |
| EA010583B1 (ru) | 2008-10-30 |
| ATE453620T1 (de) | 2010-01-15 |
| JP2006525298A (ja) | 2006-11-09 |
| AU2004234125A1 (en) | 2004-11-11 |
| US7504522B2 (en) | 2009-03-17 |
| MXPA05011670A (es) | 2005-12-15 |
| NO20055654L (no) | 2006-01-31 |
| US20070054891A1 (en) | 2007-03-08 |
| WO2004096763A1 (en) | 2004-11-11 |
| NZ543016A (en) | 2009-03-31 |
| EP1620395A1 (en) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200508831B (en) | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders | |
| ZA200508835B (en) | The use of azetidinecarboxamide derivatives in therapy | |
| US20090181939A1 (en) | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | |
| US6734176B2 (en) | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | |
| AU2004203078B2 (en) | Azetidine derivatives, their preparation and medicaments containing them | |
| FR2829028A1 (fr) | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de | |
| Cowley et al. | Recent advances in the cannabinoids | |
| US6403574B1 (en) | Azetidinecarboxamide derivatives for treating CNS disorders | |
| US6514961B1 (en) | Azetidinecarboxamide derivatives for the treatment of CNS disorders | |
| JP5259970B2 (ja) | 薬物依存症治療剤 | |
| EP1049670B1 (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| EP1212054A2 (en) | Azetidine compounds in cns and eye diseases | |
| WO2001007043A1 (en) | Azetidine carboxamide derivatives for the treatment of cns disorders | |
| EP1196165A2 (en) | Azetidine compounds in cns and eye diseases |